Genetically engineered bacterium with high yield of D-pantothenic acid as well as construction method and application of genetically engineered bacterium

Through CRISPR-Cas9 gene editing technology, the gene expression and sugar uptake path of D-pantothenic acid strain were optimized, and the problem of low D-pantothenic acid yield in microbial fermentation was solved, and efficient D-pantothenic acid production and fermentation process stability was achieved.

CN118910112APending Publication Date: 2024-11-08ZHEJIANG UNIV OF TECH

Patent Information

Application Number
CN202411070975.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The current microbial fermentation method produces D-pantothenic acid strains with low yield and unstable fermentation process, making it difficult to build high-yield D-pantothenic acid strains.

Method used

CRISPR-Cas9 gene editing technology is used to overexpress glF and glK genes, increase the copy number of panC genes, dynamically regulate coaA gene expression, and use sRNA and Hfq protein to inhibit ptsH gene expression, optimize sugar uptake and carbon flux flow to D- Pantothenic acid synthesis.

Benefits of technology

The shake flask titer of D-pantothenic acid was significantly improved to reach 7.81 g/L, an increase of 12.29% compared with the starting strain, and the fermentation process was stabilized.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910112A_ABST
    Figure CN118910112A_ABST
Patent Text Reader

Abstract

The invention provides a genetically engineered bacterium for high-yield D-pantothenic acid as well as a construction method and application of the genetically engineered bacterium. On the basis of existing engineering bacteria, heterologous glF genes and glK genes are overexpressed to enhance sugar uptake of a non-PTS system, glucose transport of the strain is improved, the requirements of cells for energy and other metabolites are met, and the growing power of the genetically engineered bacteria is enhanced; meanwhile, the expression level of a key gene panC in a D-pantothenic acid synthesis route is further enhanced, so that the carbon flux flows to the synthesis of D-pantothenic acid; generation of pantothenic acid by-products is reduced by dynamically regulating and controlling the pantothenic acid kinase coding gene coaA; finally, the Hfq protein participates in the interaction process of the non-coding RNA and the target mRNAs of the non-coding RNA, ptsH gene translation is inhibited, and therefore uptake of glucose by a PTS system is weakened. The shake-flask titer of the strain D-pantothenic acid constructed by the method reaches 7.81 g / L and is improved by 12.29% compared with that of an original strain.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering, and specifically relates to a genetically engineered bacterium with high D-pantothenic acid production and a construction method thereof, as well as application of the genetically engineered bacterium with high D-pantothenic acid production in preparing D-pantothenic acid by microbial fermentation. Background Art

[0002] D-Pantothenic acid (D-PA), also known as pantothenic acid and vitamin B5 (VB5), is a water-soluble vitamin and a member of the vitamin B group. As a component of coenzyme A (CoA) and acyl carrier protein (ACP), D-pantothenic acid participates in a variety of biochemical reactions such as energy metabolism, fatty acid synthesis, and protein metabolism, plays an important biological function, and is essential for maintaining normal physiological functions. At present, the chemical enzyme method is the mainstream method for industrial production of D-pantothenic acid. With the rapid development of synthetic biology, microbial fermentation has attracted much attention because it is more in line with the green development concept of carbon peak and carbon neutrality than traditional methods. However, there are still defects in the production of D-pantothenic acid using microbial fermentation methods, such as unstable fermentation process and low yield. Therefore, constructing a higher-yielding D-pantothenic acid strain is still a major challenge. Summary of the invention

[0003] In order to solve the technical problem of low yield of D-pantothenic acid synthesized by microbial fermentation in the prior art, the present invention uses rational design and CRISPR-Cas9 gene editing technology to provide a method for constructing a genetically engineered bacterium with high yield of D-pantothenic acid, and the application of the genetically engineered bacterium in the preparation of D-pantothenic acid by microbial fermentation.

[0004] The technical scheme adopted by the present invention is: a method for constructing a genetically engineered bacterium with high D-pantothenic acid production, the method comprising: using CRISPR-Cas9-mediated gene editing technology to: overexpress glF gene and glK gene in the genome of a starting strain; increase the copy number of panC gene; use a dynamic regulation promoter to control the expression of coaA gene; dynamically inhibit the expression of ptsH gene; obtain the genetically engineered bacterium with high D-pantothenic acid production; wherein the method for dynamically inhibiting the expression of ptsH gene comprises: dynamically inhibiting the expression of ptsH gene by using sRNA with ptsH as a target; or dynamically inhibiting the expression of ptsH gene by using sRNA with ptsH as a target and overexpressing RNA molecular chaperone Hfq gene.

[0005] refer to Figure 1The present invention is based on the starting strain DPAH8 (E. coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T ), we applied a system metabolic engineering strategy and CRISPR / Cas9 gene editing technology to (1) strengthen the non-PTS system by overexpressing the glF gene from Zymomonas mobilis and the glK gene from Escherichia coli, and effectively improve the glucose utilization rate by taking up sugar through dual channels; (2) increase the copy number of the key gene panC in the pantothenate biosynthesis pathway in Escherichia coli, and further direct the carbon flux to the synthesis of D-pantothenate; (3) use a dynamic regulatory promoter to control the pantothenate kinase encoding gene coaA to reduce the generation of pantothenate metabolic byproducts; (4) use sRNA targeting the ptsH gene and the RNA molecular chaperone hfQ to dynamically inhibit the expression of the ptsH gene, thereby inhibiting the uptake of glucose by the PTS system; ultimately, the D-pantothenate shake flask titer increased by 12.29% relative to the starting strain, reaching 7.81 g / L.

[0006] Preferably, the starting strain is Escherichia coli W3110, Trc-EcilvD* / BspanBA* / CgpanC* / alsS* / BspanB* / nacGTG / ΔP345ptsH / gltAGTG / gltATTG / Trc-PpfkB / Trc-gcvTHP / lafU::folP / yeeP::Trc-Apt2#82-serAglyA-PpanB-panB / gapC::Trc-alsS*, hereinafter referred to as engineered bacterium DPAH8. The construction method of engineered bacterium DPAH8 comprises the following steps: using engineered bacterium DPAP2 (E. coli W3110, Trc-EcilvD* / BspanBA* / CgpanC* / alsS* / BspanB* / nac GTG / ΔP 345ptsH / gltA GTG / gltA TTG / Trc-PpfkB, disclosed in CN116590209A) is a chassis bacteria, and the CRISPR-Cas9-mediated gene editing technology is used to replace the gcvTHP gene in situ promoter with the Ptrc promoter in the chassis bacteria genome; add a copy of the folP gene at the lafU pseudogene site; integrate the serA and glyA gene clusters and add a copy of the panB gene regulated by the PpanB promoter after the serAglyA gene cluster, and the serAglyA gene cluster is regulated by the dynamic regulatory element ribosomal switch Apt2#82; add the alsS gene derived from Bacillus subtilis and codon-optimized, and construct the engineered bacterium DPAH8. Among them, the nucleotide sequences of the gcvTHP gene, folP gene, and alsS gene regulated by the Ptrc promoter are shown in SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9, respectively; the serAglyA gene cluster sequence regulated by the Apt2#82 ribosomal switch is shown in SEQ ID NO.10; and the nucleotide sequence of the panB gene regulated by the PpanB promoter is shown in SEQ.ID.NO.11.

[0007] Preferably, the method for overexpressing the glF gene and the glK gene comprises: replacing the original pseudogene tfaD on the genome of the starting strain with the glF gene (abbreviated as zglF) from Zymomonas mobilis and the glK gene from Escherichia coli regulated by the Ptrc promoter. By enhancing the expression intensity of zglF and glK, the sugar uptake of the non-PTS system is enhanced, the glucose transport of the strain is improved, the cell's demand for energy and other metabolites is met, and the growth of the genetically engineered bacteria is enhanced.

[0008] Preferably, the method for increasing the number of panC gene copies comprises: replacing the original pseudogene eaeH on the genome of the starting strain with the panC gene from Bacillus subtilis or Escherichia coli regulated by the PpanB promoter; more preferably, replacing the original pseudogene eaeH on the genome of the starting strain with the panC gene from Bacillus subtilis regulated by the PpanB promoter. By strengthening the number of panC copies in the pantothenic acid synthesis pathway in Escherichia coli, the carbon flux is further directed to the synthesis of D-pantothenic acid.

[0009] Preferably, the method of controlling the expression of the coaA gene by dynamically regulating the promoter comprises: replacing the coaA gene in situ promoter on the genome of the starting strain with the Pflic promoter. By dynamically regulating the expression intensity of the coaA gene, the generation of pantothenic acid metabolic byproducts is reduced, phosphoenolpyruvate is saved, and the central carbon flow into TCA is reduced.

[0010] Preferably, the method of dynamically inhibiting ptsH gene expression using sRNA targeting ptsH includes: constructing a targeting binding sequence Anti-ptsH with ptsH as the target; using pACYC as the backbone plasmid to construct a plasmid Pr-ptsH-sRNA containing a scaffold sequence So-MicC and a targeting binding sequence Anti-ptsH; and introducing the plasmid Pr-ptsH-sRNA into the starting strain.

[0011] Preferably, the method of dynamically inhibiting ptsH gene expression by using sRNA targeting ptsH and overexpressing RNA molecular chaperone Hfq gene includes: constructing a targeting binding sequence Anti-ptsH with ptsH as the target; using pACYC as the backbone plasmid, constructing a plasmid Pr-ptsH-sRNA-Ptrc-Hfq containing the scaffold sequence So-MicC, the targeting binding sequence Anti-ptsH and the RNA molecular chaperone Hfq gene; and introducing the plasmid Pr-ptsH-sRNA-Ptrc-Hfq into the starting strain. Hfq protein is used to participate in the interaction process between non-coding sRNA and its target mRNAs. After Hfq protein binds to sRNA, the stability of mRNAs is affected, so that the ribosome binding site (RBS) of the target mRNA is isolated, which plays a role in inhibiting the translation of ptsH, thereby weakening the uptake of glucose by the PTS system, enhancing the uptake of glucose by the non-PTS system, and effectively improving the glucose utilization rate.

[0012] Preferably, the nucleotide sequences of the glF gene and glK gene regulated by the Ptrc promoter are shown as SEQ ID NO.1; the nucleotide sequence of the panC gene regulated by the PpanB promoter is shown as SEQ ID NO.2 or SEQ ID NO.3; the nucleotide sequence of the coaA gene regulated by the Pflic promoter is shown as SEQ ID NO.4; the nucleotide sequence of the sRNA targeting ptsH regulated by the Pr promoter is shown as SEQ ID NO.5; the nucleotide sequence of the Hfq gene regulated by the Ptrc promoter is shown as SEQ ID NO.6.

[0013] Preferably, the method comprises:

[0014] (1) Using the engineered bacterium DPAH8 as the starting strain, the CRISPR-Cas9-mediated gene editing technology was used to replace the original pseudogene tfaD on the genome of the starting strain with the zglF gene and glK gene regulated by the Ptrc promoter from pTrc99A, thereby obtaining the engineered bacterium DPAH8 derivative, tfaD::Ptrc-glF, glK, recorded as the engineered bacterium DPAH9;

[0015] (2) Using the engineered bacterium DPAH9 as the starting strain, the CRISPR-Cas9-mediated gene editing technology was used to replace the original pseudogene eaeH in the genome of the starting strain with the BspanC gene regulated by the PpanB promoter from pTrc99A, and the engineered bacterium DPAP8 derivative, eaeH::PpanB-BspanC, was obtained, which was recorded as the engineered bacterium DPAH10;

[0016] (3) Using the engineered bacteria DPAP10 as the starting strain, the CRISPR-Cas9-mediated gene editing technology was used to replace the original promoter of the coaA gene on the genome of the starting strain with the Pflic promoter derived from pTrc99A to obtain the engineered bacteria DPAP10 derivative, PcoaA::Pflic, recorded as engineered bacteria DPAP12;

[0017] (4) Using ptsH as the target, construct the targeting binding sequence Anti-ptsH; using pACYC as the backbone plasmid, construct the plasmid Pr-ptsH-sRNA-Ptrc-Hfq containing the scaffold sequence So-MicC, the targeting binding sequence Anti-ptsH and the RNA molecular chaperone Hfq gene; the plasmid Pr-ptsH-sRNA-Ptrc-Hfq was introduced into the engineered bacteria DPAP12 to obtain the engineered bacteria DPAH12derivative, Pr-ptsH-sRNA-Ptrc-Hfq, which was recorded as the engineered bacteria DPAH14.

[0018] The present invention also provides a genetically engineered bacterium with high D-pantothenic acid production obtained by the above method. Through the above method, the present invention obtains a genetically engineered bacterium with high D-pantothenic acid production, and the shake flask titer of the strain reaches 7.81 g / L, which is 12.29% higher than that of the starting strain.

[0019] The present invention also provides the use of the above-mentioned genetically engineered bacteria with high D-pantothenic acid production in the preparation of D-pantothenic acid by microbial fermentation. The method of the use comprises: inoculating the genetically engineered bacteria with high D-pantothenic acid production into a fermentation medium, carrying out fermentation culture at 28-37° C. and 300-450 rpm for 72-96 hours, and after the fermentation is completed, separating and purifying the supernatant of the fermentation liquid to obtain the D-pantothenic acid.

[0020] Preferably, the fermentation medium is composed of: 10-30 g / L glucose, 10-25 g / L ammonium sulfate, 1-5 g / L anhydrous betaine, 1-5 g / L yeast powder, 1-5 g / L potassium dihydrogen phosphate, 0.5-2 g / L anhydrous magnesium sulfate, 1-5 g / L β-alanine, 1-5 ml / L trace element solution, the solvent is deionized water, and the pH value is natural; the trace element solution consists of: 10 g / L CuCl2, 10 g / L FeSO4·7H2O, 10 g / L ZnSO4·7H2O, 0.2 g / L CuSO4, 0.02 g / L NiCl2·7H2O, and the solvent is deionized water.

[0021] Beneficial effects of the present invention:

[0022] The present invention uses CRISPR / Cas9 gene editing technology, and on the basis of existing engineering bacteria, overexpresses zglF gene and glK gene to enhance sugar uptake of non-PTS system, improve glucose transport of the strain, meet the cell's demand for energy and other metabolites, and strengthen the growth of genetically engineered bacteria; at the same time, further enhances the expression level of panC, a key gene in the D-pantothenic acid synthesis pathway, so that carbon flux flows to the synthesis of D-pantothenic acid; dynamically regulates the pantothenate kinase encoding gene coaA to reduce the generation of pantothenic acid byproducts; finally, Hfq protein is used to participate in the interaction process between non-coding RNA and its target mRNAs, affecting the stability of mRNAs so that the ribosome binding site (RBS) of the target mRNA is isolated, which plays a role in inhibiting the translation of ptsH gene, thereby weakening the uptake of glucose by PTS system. The strain D-pantothenic acid shake flask titer thus constructed reaches 7.81g / L, which is 12.29% higher than the starting strain. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The diagram shows the metabolic pathway of D-pantothenic acid and the modification sites.

[0024] Figure 2 The OD600 and D-pantothenic acid titer changes of DPAH9 in Example 1.

[0025] Figure 3 The OD600 and D-pantothenic acid titer changes of DPAH10 in Example 2.

[0026] Figure 4 The OD600 and D-pantothenic acid titer changes of DPAH11 in Example 3.

[0027] Figure 5 The OD600 and D-pantothenic acid titer changes of DPAH12 in Example 4.

[0028] Figure 6The OD600 and D-pantothenic acid titer changes of DPAH13 in Example 5.

[0029] Figure 7 The OD600 and D-pantothenic acid titer changes of DPAH14 in Example 6. DETAILED DESCRIPTION

[0030] The following is an explanation of the embodiments of the present invention by specific specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied by other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that, in the absence of conflict, the features in the following embodiments and embodiments can be combined with each other. In the embodiments of the present invention, the methods used are all conventional methods unless otherwise specified, and the reagents used can be obtained from commercial sources.

[0031] In the following examples, the final concentration of spectinomycin in the culture medium is 0.05 mg / L, and the final concentration of kanamycin in the culture medium is 0.05 mg / L.

[0032] The parent strain E. coli W3110 of the present invention is from the Coli Genetic Stock Center of Yale University, with a deposit date of August 5, 1975 and a deposit number of CGSC#4474, and has been disclosed in patents US2009 / 0298135A1 and US2010 / 0248311A1.

[0033] The HPLC determination method of D-pantothenic acid content is as follows: chromatographic conditions: C18 column (250×4.6mm, particle size 5μm, Agilent Technologies Co., Santa Clara, CA, USA), detection wavelength: 200nm, column temperature: 30°C; sample treatment: dilute the sample with ultrapure water to keep the D-pantothenic acid content between 0.05g / L and 0.40g / L; mobile phase: acetonitrile / water / phosphoric acid: (50 / 949 / 1); data acquisition time: 25min.

[0034] Example 1: DPAH9 construction and shake flask fermentation

[0035] DPAH8 (Escherichia coli W3110, Trc-EcilvD* / BspanBA* / CgpanC* / alsS* / BspanB*

[0036] / nacGTG / ΔP345ptsH / gltAGTG / gltATTG / Trc-PpfkB / Trc-gcvTHP / lafU::folP

[0037] / yeeP::Trc-Apt2#82-serAglyA-PpanB-panB / gapC::Trc-alsS*) was used as the starting strain, and the CRISPR-Cas9-mediated gene editing technology was used to replace the original pseudogene tfaD on the genome of the starting strain with the zglF gene and glK gene (nucleotide sequence as shown in SEQ ID NO.1) regulated by the Ptrc promoter through gene knock-in to enhance the expression intensity of non-PTS.

[0038] (1) Construction of pTarget-tfaD plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and tfaD-PAM-F / tfaD-PAM-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-tfaD plasmid, which was used for subsequent ligation of tfaD-up, tfaD-down and Donor DNA.

[0039] (2) Construction of pTD-glF-glK plasmid: Using the E. coli W3110 genome as a template, tfaD-up was amplified using primers tfaD-up-F and tfaD-up-R, tfaD-down was amplified using primers tfaD-down-F and tfaD-down-R, and pTarget-tfaD plasmid was amplified using primers PT-tfad-XF and PT-tfad-XR to obtain pTarget-X-tfaD. Then, Zymomonas mobilis and E. coli W3110 genomes were used as templates, and primers glF-F / R and glK-F / R were used for amplification according to the PCR amplification system. The glF-glk gene fragment with the promoter Ptrc was amplified and verified by agarose nucleic acid electrophoresis. The DNA fragment was recovered using a Clean up kit; pTarget-X-tfaD, Ptrc-glF-glk, tfaD-up and tfaD-down were connected together according to the instructions of (One step clone kit, Vazyme Biotech, Nanjing, China), and the pTD-Ptrc-glF-glK plasmid was obtained by sequencing verification.

[0040] (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into DPAH8, and the monoclonal colony was transferred to an LB test tube containing 0.05 mg / L kanamycin and cultured at 30°C overnight; then, the inoculum was inoculated into a 250 mL shake flask containing 50 mL LB medium at a volume concentration of 1%, and 500 μl 1 mol / L L-arabinose was added, and the culture was carried out at 150 rpm and 30°C until the OD 600 0.4~0.6; 4000rpm, 4℃ centrifugation for 10min to collect cells and prepare electroporation competent cells. For detailed process, see (Molecular Cloning: A Laboratory Manual, 3ed Edition, 99-102).

[0041] (4) Use a pipette to take an appropriate amount of pTD-Ptrc-glF-glK plasmid (about 200 ng) and mix it with 100 μl of electroporation competent cells prepared in advance, and transfer them into a pre-cooled 2 mm electroporation cup. After an ice bath for about 1-2 minutes, use an electroporator (MicroPluser TM , BIO-RAD) for electroporation transformation. After the electroporation, 800 μl LB medium was immediately added and gently aspirated, and the culture was transferred to a 2 mL Eppendorf tube. After reviving at 30°C for 3-4 hours, it was coated with LB solid plates containing 0.05 mg / L kanamycin and 0.05 mg / L spectinomycin, and inverted culture was carried out at 30°C for 12-16 hours. Colony PCR was performed using tfaD-VF / R as primers to verify. If a fragment of about 4000 bp was successfully cloned, it was proved to be a DPAH9 (DPAH8 derivative tfaD:-Ptrc-glF-glK) positive colony.

[0042] (5) Plasmid elimination: Use an inoculation loop to pick a positive single colony and inoculate it into 1 mM IPTG and 0.05 mg / L kanamycin were placed in an LB liquid test tube and cultured at 30°C overnight. The next day, the bacterial liquid was streaked on an LB solid plate containing 0.05 mg / L kanamycin and cultured at 30°C for 24 hours. When the bacteria grew to a certain size, some single colonies were picked and streaked on an LB plate containing 0.05 mg / L spectinomycin. Single colonies that could not be on the LB plate containing 0.05 mg / L spectinomycin showed that the pTarget-tfaD plasmid was successfully eliminated. Then, single colonies with successful elimination of the pTarget-tfaD plasmid were picked and placed in an LB test tube and cultured at 37°C overnight to eliminate the pCas plasmid. The next day, the bacterial liquid was streaked on an LB plate. After culturing at 37°C for 12 hours, some single colonies were picked and streaked on an LB plate containing 0.05 mg / L kanamycin. Single colonies that could not be on the LB plate containing 0.05 mg / L kanamycin showed that the pCas plasmid was successfully eliminated, and finally the plasmid-free strain DPAH9 (DPAH8 derivative, tfaD:Ptrc-glF-glK).

[0043] (6) Shake flask fermentation: DPAH9 and the starting strain DPAH8 in the control group were inoculated into 10 mL of LB medium, respectively, and cultured at 37°C and 200 rpm as pre-cultures; after 8-12 hours, 1 mL of the pre-culture was inoculated into a 500 mL shake flask containing 50 mL of MS medium at a 2% inoculum, and then cultured in a constant temperature shaker at 30°C and 180 rpm for 48 hours for strain fermentation; after the fermentation was completed, 1 mL of the fermentation liquid was taken to measure the OD 600 At the same time, 1 mL of fermentation liquid was drawn with a pipette, and centrifuged at 12000 rpm for 3 min at room temperature. The fermentation supernatant was diluted 5 times, and the diluted sample was treated with a water filter membrane to remove impurities. HPLC detection was performed according to Example 1, and OD 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 2 shown.

[0044] As can be seen from the figure, the additional increase in the copy number of zglF and glK genes in the genome has no obvious effect on bacterial growth. At the same time, it promotes the increase in the titer of D-pantothenic acid in shake flasks, which is about 7.2g / L, and improves the sugar transport capacity. Considering the needs of subsequent transformation, the strain will continue to be transformed on this basis.

[0045] LB medium: 10 g / L peptone, 5 g / L yeast extract, 5 g / L NaCl, solvent is deionized water, pH value is natural.

[0046] MS culture medium: glucose 20g / L, (NH4)2SO416 g / L, KH2PO42 g / L, MgSO40.5 g / L, yeast extract 2g / L, CaCO310 g / L, 1ml / L trace element solution, the solvent is deionized water, pH value is natural; 10g / L calcium carbonate (sterilized separately); the trace element solution composition is: 10g / L CuCl2, 10g / L FeSO4·7H2O, 1g / LZnSO4·7H2O, 0.20g / LCuSO4, 0.02g / LNiCl2·7H2O, the solvent is deionized water.

[0047] Example 2: DPAH10 construction and shake flask fermentation

[0048] Using DPAH9 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to knock in the ecjpanC gene regulated by the PpanB promoter from pTrc99A. *224M The gene (nucleotide sequence is shown in SEQ ID NO.2) replaces the original pseudogene eaeH in the genome of the starting strain to enhance the ecjpanC *224M intensity of expression.

[0049] (1) Construction of pTarget-eaeH plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pT-eaeH-F / R as primers for PCR amplification. The PCR product was verified by nucleic acid gel electrophoresis and digested with Dpn I digestion enzyme at 37°C for 3 h. The product was then transformed into E. coli DH5α and screened on a spectaclease plate. The correct pTarget-eaeH plasmid was obtained by sequencing for subsequent ligation with Donor DNA.

[0050] (2) Construction of pTD-ecjpanC *224M Plasmid: First, using the E. coli W3110 genome as a template, eaeH-up-F / R as primers were used to amplify the upstream part of the donor DNA (F1), and eaeH-down-F / R as primers were used to amplify the downstream part of the donor DNA (F2). Then, using the E. coli W3110 genome as a template, ecjpanC with the promoter ppanB was amplified using ecjpanc-F / R as primers. *224M Gene fragment (F3), PCR fragments were purified by gel recovery to obtain F1, F2 and F3; plasmid pTarget-eaeH was incubated at 37°C for 8 h with Xba I and Pst I, and DNA fragments were recovered by Clean up kit; according to (One step cloning kit, Vazyme Biotech, Nanjing, China) instructions to connect the pTarget-eaeH vector, fragments F1, F2 and F3 together, and obtain pTD-panB-ecjpanC by sequencing verification. *224M Plasmid.

[0051] (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the DPAH9 competent cell obtained in Example 1. The method for preparing the DPAH9 competent cell by electroporation was the same as that in Example 1 (3).

[0052] (4) DPAH10 positive colonies were constructed using the same method as in Example 1 (4).

[0053] (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free DPAH10.

[0054] (6) The constructed DPAH10 production strain was used as a control group with the DPAH9 constructed in Example 1, and the shake flask test and detection were carried out according to the method of Example 1 (6). 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 3 shown.

[0055] As can be seen from the figure, the ecjpanC gene was increased by gene knock-in in the genome *224M After the gene copy number was increased, there was no effect on bacterial growth, but the D-pantothenic acid shake flask titer increased to 7.41g / L. It may be that the introduction of this gene caused pantothenic acid and β-alanine to shift to the synthesis of pantothenic acid, thereby promoting the biosynthesis of D-pantothenic acid in the strain.

[0056] Example 3: DPAH11 construction and shake flask fermentation

[0057] Using DPAH9 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to replace the original pseudogene eaeH on the genome of the starting strain with the BSpanC gene (nucleotide sequence as shown in SEQ ID NO.3) regulated by the PpanB promoter derived from pTrc99A through gene knock-in to enhance the expression intensity of BSpanC.

[0058] (1) Construction of pTarget-eaeH plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pT-eaeH-F / R as primers for PCR amplification. The PCR product was verified by nucleic acid gel electrophoresis and digested with Dpn I digestion enzyme at 37°C for 3 h. The product was then transformed into E. coli DH5α and screened on a spectaclease plate. The correct pTarget-eaeH plasmid was obtained by sequencing for subsequent ligation with Donor DNA.

[0059] (2) Construction of pTD-bspanC plasmid: First, using the E. coli W3110 genome as a template, eaeH-up-F / R as primers were used to amplify the upstream part of the donor DNA (F1), and eaeH-down-F / R as primers were used to amplify the downstream part of the donor DNA (F2). Then, using the Bacillus subtilis168 genome as a template, bspanc-F / R as primers were used to amplify the bspanC gene fragment (F3) with the promoter ppanB, and the PCR fragments were purified by gel recovery to obtain F1, F2 and F3; the plasmid pTarget-eaeH was incubated at 37°C for 8 hours with Xba I and Pst I, and the DNA fragments were recovered using the Clean up kit; according to The pTarget-ompT vector, fragments F1, F2 and F3 were connected together according to the instruction manual of the kit (One step cloning kit, Vazyme Biotech, Nanjing, China), and the pTD-bspanC plasmid was obtained by sequencing verification.

[0060] (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the DPAH9 competent cell obtained in Example 2. The preparation method of the DPAP8 competent cell by electroporation was the same as that in Example 1 (3).

[0061] (4) DPAH11 positive colonies were constructed using the same method as in Example 1 (4).

[0062] (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free DPAH11.

[0063] (6) The constructed DPAP8 production strain was used as a control group with the DPAP8 constructed in Example 2, and shake flask tests and detection were performed according to the method of Example 1 (6). 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 4 shown.

[0064] As can be seen from the figure, increasing the copy number of the heterologous bspanC gene by gene knock-in in the genome did not significantly affect the growth of the strain, and the D-pantothenic acid shake flask titer was slightly increased to 7.45 g / L, which was higher than that of E. coli panC *224M big.

[0065] Example 4: DPAH12 construction and shake flask fermentation

[0066] Using DPAH11 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to replace the coaA gene regulated by the original promoter on the genome of the starting strain with the coaA gene regulated by the Pflic promoter derived from pTrc99A (nucleotide sequence as shown in SEQ ID NO.4) through gene knock-in, so as to dynamically regulate the expression intensity of coaA.

[0067] (1) Construction of pTarget-coaA plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pT-coaA-F / R as primers for PCR amplification. The PCR product was verified by nucleic acid gel electrophoresis and digested with Dpn I digestion enzyme at 37°C for 3 h. The product was then transformed into E. coli DH5α and screened on a spectaclease plate. The correct pTarget-coaA plasmid was obtained by sequencing for subsequent ligation with Donor DNA.

[0068] (2) Construction of pTD-coaA plasmid: First, using the E. coli W3110 genome as a template, coaA-up-F / R as primers were used to amplify the upstream part of the donor DNA (F1), and coaA-down-F / R as primers were used to amplify the downstream part of the donor DNA (F3). Then, using the E. coli W3110 genome as a template, fliC-oA-F / R as primers were used to amplify the coaA gene fragment (F2) with the promoter pflic, and the PCR fragments were purified by gel recovery to obtain F1, F2 and F3; the plasmid pTarget-coaA was incubated at 37°C for 8 hours with Xba I and Pst I, and the DNA fragments were recovered using the Clean up kit; according to The pTarget-coaA linearized vector, fragments F1, F2, and F3 were connected together according to the instruction manual of the kit (Onestep clone kit, Vazyme Biotech, Nanjing, China), and the pTD-coaA plasmid was obtained by sequencing verification.

[0069] (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the DPAH11 competent cell obtained in Example 3. The preparation method of the DPAH11 competent cell by electroporation was the same as that in Example 1 (3).

[0070] (4) DPAH12 positive colonies were constructed using the same method as in Example 1 (4).

[0071] (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free DPAH12.

[0072] (6) The constructed DPAH12 production strain was used as a control group with the DPAH11 constructed in Example 3, and the shake flask test and detection were carried out according to the method of Example 1 (6). 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 5 shown.

[0073] As can be seen from the figure, by dynamically regulating the coaA gene on the genome, the D-pantothenic acid shake flask titer was increased to 7.51 g / L, reducing the production of pantothenic acid byproduct coA, thereby increasing the production of pantothenic acid.

[0074] Example 5: DPAH13 construction and shake flask fermentation

[0075] Using DPAH12 as the starting strain, sRNA was used to dynamically inhibit the expression of the ptsH gene (nucleotide sequence as shown in SEQ ID NO.5) on the PACYC plasmid to obtain the engineered bacteria DPAH13 derivative, Pr-ptsH-sRNA, to further regulate the expression intensity of ptsH.

[0076] (1) Construction of Pr-ptsH-sRNA plasmid: The ptsH gene regulated by the Pr promoter was connected to pACYC. After sRNA was transcribed, ptsH was interfered with to varying degrees. First, the E. coli W3110 genome was used as a template and Pr-ptsH-F / R was used as primers to amplify donor DNA. The PCR fragment was purified by gel recovery to obtain F1, and micc-F / R was used as primers to amplify the downstream part (F2) of the donor DNA; according to (One step clone kit, Vazyme Biotech, Nanjing, China) Instructions PACYC linearized vector, fragment F1, and fragment F2 were sequenced to obtain Pr-ptsH-sRNA plasmid. The constructed Pr-ptsH-sRNA plasmid was introduced into DPAH12 to obtain DPAH13 strain. The DPAH12 electroporation competent preparation method was the same as in Example 1 (3).

[0077] (2) The constructed DPAH13 production strain was used as a control group with the DPAP12 constructed in Example 4, and the shake flask test and detection were carried out according to the method of Example 1 (6). 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 6 shown.

[0078] As can be seen from the figure, by interfering with the ptsH gene to varying degrees on the genome, the D-pantothenic acid production still increased significantly, about 7.68g / L. After the ptsH gene was inhibited, the strain growth decreased slightly, but the sugar utilization efficiency was improved, thereby enhancing the D-pantothenic acid production.

[0079] Example 6: DPAH14 construction and shake flask fermentation

[0080] Using DPAH12 as the starting strain, sRNA was used on the PACYC plasmid to dynamically inhibit the expression of the ptsH gene, and the RNA molecular chaperone Hfq was overexpressed to further regulate the expression intensity of ptsH.

[0081] (1) Construction of Pr-ptsH-sRNA-Ptrc-Hfq plasmid: The ptsH gene regulated by the Pr promoter was connected to pACYC. After transcribing sRNA, it binds to the Hfq protein, which interferes with ptsH to a greater extent. First, the E. coli W3110 genome was used as a template and Pr-ptsH-F / R was used as primers to amplify donor DNA. The PCR fragment was purified by gel recovery to obtain F1. The midstream part (F2) of the donor DNA was amplified using micc-F / R as primers, and the downstream part (F3) of the donor DNA was amplified using hfq-F / R as primers. (One step clone kit, Vazyme Biotech, Nanjing, China) Instructions PACYC linearized vector, fragment F1, and fragment F2 were verified by sequencing to obtain Pr-ptsH-sRNA-Ptrc-Hfq plasmid. The constructed Pr-ptsH-sRNA-Ptrc-Hfq plasmid was introduced into DPAH12 to obtain DPAH14 strain. The DPAH12 electroporation competent preparation method was the same as Example 1 (3).

[0082] (2) The constructed DPAH14 production strain was used as a control group with the DPAH12 constructed in Example 4, and the shake flask test and detection were carried out according to the method of Example 1 (6). 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 6 shown.

[0083] As can be seen from the figure, further interference with the ptsH gene on the genome still significantly increased the D-pantothenic acid production to about 7.81 g / L. This strategy improves the product conversion rate without damaging the PTS system, thereby enhancing the D-pantothenic acid production.

[0084] The primer sequence information used in Examples 1 to 6 is shown in Table 1.

[0085] Table 1. Primer sequences

[0086]

[0087] The embodiments described above are merely descriptions of preferred implementations of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope of the present invention.

Claims

1. A method for constructing a genetically engineered bacterium that produces high levels of D-pantothenic acid, characterized in that: The method comprises: using CRISPR-Cas9-mediated gene editing technology to: overexpress glF gene and glK gene in the genome of the starting strain; increase the copy number of panC gene; control the expression of coaA gene by dynamically regulating the promoter; dynamically inhibit the expression of ptsH gene; and obtain a genetically engineered bacterium with high production of D-pantothenic acid; The method for dynamically inhibiting ptsH gene expression includes: dynamically inhibiting ptsH gene expression using sRNA targeting ptsH; or dynamically inhibiting ptsH gene expression using sRNA targeting ptsH and overexpressing RNA molecular chaperone Hfq gene.

2. The method according to claim 1, characterized in that The starting strain is Escherichia coli W3110, Trc-EcilvD* / BspanBA* / CgpanC* / alsS* / BspanB* / nacGTG / ΔP345ptsH / gltAGTG / gltATTG / Trc-PpfkB / Trc-gcvTHP / lafU::folP / yeeP::Trc-Apt2#82-serAglyA-PpanB-panB / gapC::Trc-alsS*.

3. The method according to claim 1, characterized in that The method for overexpressing the glF gene and the glK gene comprises: replacing the original pseudogene tfaD on the genome of the starting strain with the glF gene from Zymomonas mobilis and the glK gene from Escherichia coli regulated by the Ptrc promoter.

4. The method according to claim 1, characterized in that The method for increasing the copy number of the panC gene comprises: replacing the original pseudogene eaeH on the genome of the starting strain with the panC gene from Bacillus subtilis or Escherichia coli regulated by the PpanB promoter.

5. The method according to claim 1, characterized in that The method for controlling the expression of the coaA gene by using a dynamic regulation promoter comprises: replacing the in situ promoter of the coaA gene on the genome of the starting strain with a Pflic promoter.

6. The method according to claim 1, characterized in that The method of dynamically inhibiting ptsH gene expression by using sRNA targeting ptsH includes: constructing a targeting binding sequence Anti-ptsH with ptsH as the target; using pACYC as the backbone plasmid to construct a plasmid Pr-ptsH-sRNA containing a scaffold sequence So-MicC and a targeting binding sequence Anti-ptsH; and introducing the plasmid Pr-ptsH-sRNA into a starting strain.

7. The method according to claim 1, characterized in that The method for dynamically inhibiting ptsH gene expression by using sRNA targeting ptsH and overexpressing RNA molecular chaperone Hfq gene includes: constructing a targeting binding sequence Anti-ptsH with ptsH as the target; using pACYC as the backbone plasmid to construct a plasmid Pr-ptsH-sRNA-Ptrc-Hfq containing a scaffold sequence So-MicC, a targeting binding sequence Anti-ptsH and an RNA molecular chaperone Hfq gene; and introducing the plasmid Pr-ptsH-sRNA-Ptrc-Hfq into a starting strain.

8. The method according to claim 1, characterized in that The nucleotide sequences of the glF gene and glK gene regulated by the Ptrc promoter are shown in SEQ ID NO.1; the nucleotide sequence of the panC gene regulated by the PpanB promoter is shown in SEQ ID NO.2 or SEQ ID NO.3; the nucleotide sequence of the coaA gene regulated by the Pflic promoter is shown in SEQ ID NO.4; the nucleotide sequence of the sRNA targeting ptsH regulated by the Pr promoter is shown in SEQ ID NO.5; the nucleotide sequence of the Hfq gene regulated by the Ptrc promoter is shown in SEQ ID NO.

6.

9. A genetically engineered bacterium with high production of D-pantothenic acid obtained by the method of any one of claims 1 to 8.

10. Use of the genetically engineered bacteria with high D-pantothenic acid production as claimed in claim 9 in the preparation of D-pantothenic acid by microbial fermentation, characterized in that: The application method comprises: inoculating the genetically engineered bacteria with high D-pantothenic acid production into a fermentation medium, carrying out fermentation culture at 28-37° C. and 300-450 rpm for 72-96 hours, and after the fermentation is completed, separating and purifying the supernatant of the fermentation liquid to obtain the D-pantothenic acid.

Citation Information

Patent Citations

  • Genetically engineered bacterium for producing D-pantothenic acid, construction method and application

    CN116590209A

  • Method for fermentative production of L-methionine

    US20090298135A1

  • Increasing methionine yield

    US20100248311A1

Cited By

  • High-yield D-pantothenic acid genetically engineered bacterium based on one-carbon unit supply and construction and application thereof

    CN119220576A

  • Genetically engineered bacterium for high yield of D-pantothenic acid without addition of inducer, construction method and application

    CN119824023A

  • A genetically engineered bacterium with high-yield D-pantothenic acid without inducer addition, construction method and application

    CN119824023B

  • High-yield D-pantothenic acid genetically engineered bacterium based on ilvY activation system as well as construction method and application of high-yield D-pantothenic acid genetically engineered bacterium

    CN121874076A